It was in a laboratory in Hull three years ago that Reckitt Benckiser first hit on the idea of combining Nurofen with paracetamol, a 100-year-old molecule, to create Nuromol.
The painkiller has become a top seller and its innovative development is part of the reason Reckitt has started a big investment programme in Hull.
The maker of Gaviscon, Nurofen and Strepsils said yesterday it would spend £100 million creating a research and development facility for its consumer healthcare division in Hull.
Reckitt plans to develop a large building on the site, where it has had a presence for 200 years, to house new consumer health laboratory facilities. It also plans to upgrade its existing R&D premises on the site significantly, which is used for its